Wnt pathway activator and CXXC5-Dishevelled interaction inhibitor

Our opinion on this compoundSingle-lab provenance

54/100

Novel CXXC5-DVL protein-protein interaction inhibitor with real Wnt probe value, bottlenecked by single-lab evidence

Look, the mechanism here is actually interesting. PTD-DBM isn’t another blunt GSK-3β inhibitor or a vague herb extract that ‘activates Wnt somehow.’ What Kang-Yell Choi’s group at Yonsei built is a competitive displacement tool: the DBM segment mimics the Dishevelled-binding motif of CXXC5, a documented negative regulator of canonical Wnt signaling, and kicks it off the Dishevelled scaffold. That releases a specific brake on Wnt propagation. The PTD (HIV-Tat derived) handles membrane crossing for the otherwise impermeable peptide. As a probe for the CXXC5-DVL interaction specifically, you cant get this question answered with CHIR99021 or lithium or any of the generic Wnt agonists that hit GSK-3β upstream. That probe specificity is real and its why the bench value score isn’t at the floor.

The hair follicle biology behind this is plausible. CXXC5 knockout mice show accelerated anagen entry and resistance to age-related thinning, which is the genetic validation you want before trusting a pharmacological mimic. The rodent alopecia models using PTD-DBM topically, including the chemotherapy-induced and androgenetic models, have been published in reasonably respectable journals. There’s even human ex vivo follicle data. That’s not nothing. And the Yonsei spin-out (CXC5, Inc.) suggests at least internal conviction that this is translatable.

Here’s the thing though: it’s all one lab. Every PTD-DBM paper traces back to the same Yonsei group or collaborators they invited in. That’s the same structural problem we flag with BPC-157 (Croatian group) and Epitalon (Khavinson consortium). Single-source preclinical means we genuinely don’t know if the effect size holds when an independent lab runs the protocol, and that uncertainty has to hit the evidence score hard. There’s no completed phase 1, no replicated hair cycle data from Tokyo or Munich or Boston. The spin-out has been ‘in early stages’ for several years, which isn’t reassuring.

What we like: the PPI-inhibitor approach to Wnt activation is a real advance over broad-spectrum tools, and the PTD conjugation strategy is validated chemistry. An investigator running a Wnt-pathway hair follicle program would find this useful as a tool compound, precisely because it lets you ask ‘what does specifically releasing the CXXC5 brake do’ in a way nothing else currently allows. What we dont like: sourcing is thin, purity verification is genuinely difficult outside dedicated peptide chemistry labs, and the dependency on a single research consortium for all meaningful data means replication risk is high. Worth tracking as the CXC5 clinical program develops. Worth running if you have peptide handling infrastructure and a Wnt or follicle biology question. Not worth anchoring a research program around yet.

Novelty: 65
Mechanism promise: 68
In-category differentiation: 58
Evidence quality: 30
Translational signal: 35
Research bench value: 58

Rationale PTD-DBM earns genuine marks on novelty and mechanism specificity, targeting a defined PPI node on the Wnt pathway that no other current tool addresses cleanly. The single-lab origin (Yonsei/Choi consortium throughout) and absence of replicated preclinical or any completed human trial data drags evidence and translational scores down sharply, landing it squarely in single-lab-only territory alongside BPC-157.

Wnt pathway activator and CXXC5-Dishevelled interaction inhibitor

A research-grade peptide that disrupts the CXXC5-Dishevelled negative regulatory complex on the canonical Wnt pathway, studied for hair follicle stimulation and tissue regeneration.

Abstract

PTD-DBM (protein transduction domain conjugated to Dishevelled-binding motif; DBM derived from the Dishevelled-PDZ-binding C-terminus of CXXC5; molecular weight approximately 4 kDa as a synthetic conjugate) is a research-grade peptide developed at Yonsei University in South Korea by Kang-Yell Choi and colleagues as a tool for activating canonical Wnt signaling at the level of the Dishevelled scaffold. The canonical Wnt pathway is a developmental signaling system that drives stem cell self-renewal, tissue regeneration, and (importantly for hair) the anagen phase of the hair follicle cycle. CXXC5 is a negative regulator of canonical Wnt signaling that binds Dishevelled at a defined motif and prevents Dishevelled-mediated signal propagation; loss of CXXC5 in knockout mice produces enhanced Wnt signaling, accelerated hair cycle entry, and resistance to age-related hair thinning. The PTD-DBM peptide is designed to mimic the CXXC5 Dishevelled-binding motif and competitively displace endogenous CXXC5 from Dishevelled, releasing canonical Wnt signal flow. The PTD (HIV-Tat-derived protein transduction domain) enables cell membrane crossing of the otherwise impermeable peptide. Reported activities in rodent and human ex vivo hair follicle models include accelerated anagen induction, increased hair shaft length, and protection against chemotherapy-induced and androgenetic alopecia in rodent models. Topical formulation with the valproic acid co-treatment (KDC-MN-1348) has been explored as a synergistic Wnt-activating combination. The compound is research-grade and not approved by any regulatory authority; clinical translation through Yonsei University spin-out CXC5 has been in early stages. Reconstitution requires aqueous buffer with co-solvent for the peptide-PTD conjugate; topical delivery in the hair-follicle context is the principal route under investigation.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1347Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: Wnt pathway activator and CXXC5-Dishevelled interaction inhibitor

PTD-DBM

Abstract

Read the full monograph